Hudson Bay Capital Management
ALXN

Hudson Bay Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Hudson Bay Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$3.48M – 975
2018
Q3 		$3.48M Buy
+25,000
New +$3.14M 0.04% 368
2016
Q3 		– Sell
-24,500
Closed -$2.86M – 534
2016
Q2 		$2.86M Buy
+24,500
New +$3.48M 0.09% 154
2013
Q4 		– Sell
-100,000
Closed -$11.6M – 190
2013
Q3 		$11.6M Buy
+100,000
New +$11M 0.43% 58

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Hudson Bay Capital Management's ALXN Position: Q3 2021 in Review

Hudson Bay Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,020,985 shares — an estimated $188M sold.

Hudson Bay Capital Management first reported a position in ALXN in Q3 2013 and held it in 23 quarters. The position peaked at $188M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Hudson Bay Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,020,985 Alexion Pharmaceuticals shares in Q3 2021, an estimated $188M.
  • Hudson Bay Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 23 quarters.
  • Hudson Bay Capital Management's Alexion Pharmaceuticals position peaked at $188M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hudson Bay Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.